+ 0.00
+ 0%
+ 0.02
+ 0.01%
+ 0.03
+ 0.01%
+ 0.00
+ 0%

9 Takeaways From The JPMorgan Healthcare Conference

January 17, 2020 2:47 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
9 Takeaways From The JPMorgan Healthcare Conference

The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare this year. 

In 2019, the conference made a splash, with Bristol-Myers Squibb Co (NYSE:BMY) announcing its multibillion-dollar purchase of Celgene just ahead of the conference and Eli Lilly And Co (NYSE:LLY) revealing its intention to buy Loxo Oncology.

Deals Conspicuous By Their Absence

The 2020 conference did not see any M&A announcements outside of Teladoc Health Inc's (NYSE:TDOC) agreement to buy enterprise telehealth solutions provider InTouch Health for $600 million. Even this deal was announced a day before the conference began. 

After a record year for M&A in 2019, biopharma acquisitions are expected to slow down a bit in the new year.

Accent On Digital Health

The conference saw discussions on digital health and wellness apps that operate on the fringes of the medical sector.

These should be curated so that doctors can decide whether they can recommend them to their patients, American Medical Association CEO James Madara was quoted as saying. 

Tech Stalwarts Join In

Tech titans such as Google parent Alphabet Inc (NASDAQ:GOOGL) (NASDAQ:GOOG), NVIDIA Corporation (NASDAQ:NVDA) and salesforce.com, inc. (NYSE:CRM) participated in the conference to discuss how new technologies such as artificial intelligence and cloud computing can be used to improve health care.

See also: NuVasive Is 'A Stock To Watch For In 2020,' SunTrust Says In Bullish Initiation

Oncology, Rare Diseases Offer Lucrative Opportunity

Biopharma companies both big and small said oncology and rare diseases are areas presenting promising opportunities.

Neuroscience A Sector to Watch In 2020

Neuroscience is being touted as a focus area.

"We think neuroscience has the potential to be in the '20s what oncology has been in the last decade," Roche Holdings AG Basel ADR (OTC:RHHBY) Pharmaceuticals CEO Bill Anderson reportedly said. 

Drug Pricing Defended

With 2020 being a U.S. presidential election year, it is a no surprise that drug companies are worried that the high cost of prescription drugs is a campaign issue. Pharma companies defended their stance by detailing the high R&D costs involved in moving a drug from the lab to the shelves.

Biogen Tightlipped On Aducanumab Filing

Despite expectations that Biogen Inc (NASDAQ:BIIB) would give a timeline for its regulatory filing for aducanumab to treat Alzheimer's, it merely suggested it is preparing modules of the common technical document for submission to the FDA.

Amgen, Bristol-Myers Exude Confidence

Amgen, Inc. (NASDAQ:AMGN) sounded very bullish, relaying a clear shift in narrative, with Otezla and overseas expansion expected from its investment in Beigene Ltd (NASDAQ:BGNE), BofA Securities analyst Geoff Meacham said in a note.

The analyst also noted that Bristol-Myers Squibb instilled confidence with its presentations given six near-term product launches and a good cadence of new data disclosures at medical meetings in the first half of 2020.

Lack of Diversity Underlined

Some attendees at the conference pointed out the lack of diversity among biopharma executives, with most being white males.

Related Link: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Related Articles

Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research

The global laryngeal cancer therapeutics market is expected to grow by $635.07 million during 2021-2025 helped by Amgen Inc (NASDAQ: AMGN) and AstraZeneca Plc (NYSE: AZN) as key contributors to growth, according to a study read more

Hearing Jefferies Calls Amgen Data On KRAS 'Good,' Notes Inline With Expectations

Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity

The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse.  read more

BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy. Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities. read more